financetom
Business
financetom
/
Business
/
Update: 10x Genomics Secures Court Injunction Against Bruker's Sale of GeoMx Products in US
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: 10x Genomics Secures Court Injunction Against Bruker's Sale of GeoMx Products in US
Dec 24, 2024 7:56 AM

10:30 AM EST, 12/24/2024 (MT Newswires) -- (Updates with Bruker's ( BRKR ) statement in the sixth and seventh paragraphs.)

10x Genomics ( TXG ) said late Monday a US court issued a permanent injunction against the sale of GeoMx products by Bruker ( BRKR ) .

The US District Court for the District of Delaware will enter the injunction in January, which will prohibit Bruker ( BRKR ) from making, using, selling, or offering to sell the GeoMx Digital Spatial Profiler and associated instruments, reagents, and services for RNA and protein detection in the US.

These products were acquired from NanoString Technologies, according to 10x Genomics ( TXG ).

To ensure the continuity of the ongoing research, 10x said it requested an exemption for GeoMx users who installed an instrument before the trial in November 2023.

Additionally, 10x said that the court upheld the November 2023 jury verdict, which awarded the company $31 million in damages after finding that NanoString's GeoMx Digital Spatial Profiler products infringed patents licensed to 10x.

Bruker ( BRKR ) on Tuesday said it disagreed with the court's decision and planned to seek a stay of any injunction that is ordered in the coming weeks.

The company said GeoMx instrument sales represented less than 0.2% of its total revenue and the court's ruling did not impact the CosMx or nCounter product lines which Bruker ( BRKR ) also acquired from NanoString.

NanoString did not immediately respond to MT Newswires' request for comment.

Price: 14.74, Change: +0.01, Percent Change: +0.07

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
nCino Insider Sold Shares Worth $193,246,817, According to a Recent SEC Filing
nCino Insider Sold Shares Worth $193,246,817, According to a Recent SEC Filing
Jul 16, 2024
03:25 AM EDT, 07/16/2024 (MT Newswires) -- Jeff Horing, 10% Owner, Director, on July 11, 2024, sold 6,219,839 shares in nCino (NCNO) for $193,246,817. Following the Form 4 filing with the SEC, Horing has control over a total of 19,771,487 shares of the company, with 117,603 shares held directly and 19,653,884 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1902733/000110465924079981/xslF345X03/tm2419507-4_4seq1.xml ...
Ensign Group Insider Sold Shares Worth $1,437,438, According to a Recent SEC Filing
Ensign Group Insider Sold Shares Worth $1,437,438, According to a Recent SEC Filing
Jul 16, 2024
03:27 AM EDT, 07/16/2024 (MT Newswires) -- Spencer Burton, President and Chief Operating Officer, on July 11, 2024, sold 10,618 shares in Ensign Group ( ENSG ) for $1,437,438. Following the Form 4 filing with the SEC, Burton has control over a total of 42,629 shares of the company, with 42,629 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1125376/000112537624000128/xslF345X03/wk-form4_1721086634.xml Price: 135.22, Change:...
H B Fuller Insider Sold Shares Worth $1,958,763, According to a Recent SEC Filing
H B Fuller Insider Sold Shares Worth $1,958,763, According to a Recent SEC Filing
Jul 16, 2024
03:29 AM EDT, 07/16/2024 (MT Newswires) -- Heather Campe, Senior Vice President, International Growth, on July 12, 2024, sold 23,696 shares in H B Fuller ( FUL ) for $1,958,763. Following the Form 4 filing with the SEC, Campe has control over a total of 19,742 shares of the company, with 19,742 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/39368/000122520824007434/xslF345X03/doc4.xml Price: 81.76,...
Novo owner backs Swiss biotech Asceneuron in $100 million round
Novo owner backs Swiss biotech Asceneuron in $100 million round
Jul 16, 2024
LONDON, July 16 (Reuters) - Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder of Wegovy maker Novo Nordisk to fund clinical development of its Alzheimer's disease drug. The Series C round was led by Novo Holdings, the investment arm of the Novo Nordisk Foundation, which will hold a board seat...
Copyright 2023-2025 - www.financetom.com All Rights Reserved